IL6 and Parkinson disease: These phenotypes are accompanied by a specific overproduction and release of IL-6, by a more than 2.5-fold increase in L2-PD astrocytes, and appear to be mediated by hyperactive LRRK2 G2019S kinase activity, corroborating the proposed role of LRRK2 as modulator of brain immune response.